bpc-157 clinical trial human 2024 2025 Orthopedic Use of An FDA Committee Just Voted

No IGF-1 elevation

Anaemia and osteoporosis After surgery to remove part or all of your stomach, your body may not absorb certain vitamins and minerals as well as before

Using combination therapies to target critical downstream signaling pathways is considered a rational approach

Author Contributions I.M.S

14.5 MOUNJARO Use in Combination with Metformin or Basal Insulin, or Both in Pediatric Patients 10 Years of Age and Older with Type 2 Diabetes Mellitus SURPASS-PEDS (NCT05260021) was a 30-week double-blind, placebo-controlled trial with a 22-week open-label extension that randomized 99 pediatric patients 10 years of age and older with type 2 diabetes mellitus with inadequate glycemic control on metformin (69%), or basal insulin (8%), or both (23%) to receive subcutaneous MOUNJARO 5 mg, MOUNJARO 10 mg, or placebo once weekly as add-on therapy